Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

27.52 -0.47 (-1.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 360,622
Open 28.21
Bid (Size) 19.00 (1)
Ask (Size) 44.03 (2)
Prev. Close 27.99
Today's Range 27.03 - 28.33
52wk Range 25.19 - 48.40
Shares Outstanding 47,260,804
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-36.58%
-36.58%
1 Month
-0.79%
-0.79%
3 Month
-18.89%
-18.89%
6 Month
-23.51%
-23.51%
1 Year
-2.93%
-2.93%

More News

Read More
Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27
Via Talk Markets
4 Analysts Have This to Say About Celldex Therapeutics
Via Benzinga
Celldex Therapeutics: Q1 Earnings Insights
Via Benzinga
Why Celldex Therapeutics Shares Are Trading Higher Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
Via Benzinga
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at Jefferies Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
From Celldex Therapeutics, Inc.
Via GlobeNewswire
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday
Via Benzinga
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
From Celldex Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.